Dear Friends & Colleagues,
I am glad to bring you warm Deepavali Wishes and the Season’s Greetings from Oviya MedSafe – your potential strategic partner for Global Pharmacovigilance, through the November 2012 edition of our monthly newsletter!
In this edition, I am happy to share with you a milestone that Oviya MedSafe has reached a few days ago – our first peer-reviewed publication!
At this juncture, I thank renowned diabetologist Dr V Mohan and his team (especially Dr S Chandru) who invited Oviya MedSafe to work along with them on an article emphasizing on the need for pharmacovigilance of the anti-diabetic drug Pioglitazone the usage of which has been linked to the causation of cancer of the urinary bladder.
Our peer-reviewed article titled ‘Need to Increase Awareness Among Urologists Regarding the Possible Association Between Pioglitazone and Bladder Cancer’ has been published in the Indian Journal of Clinical Medicine on 08-Nov-2012. The free full-text of the article can be downloaded and read by visiting the URL of the publisher http://la-press.com/article.php?article_id=3414.
We hope you will find the article interesting and we are keen to receive your feedback on this article.
Do visit us at www.oviyamedsafe.com and feel free to write to email@example.com with your thoughts.
Follow us on:
With thanks & regards,
Dr Vijay Venkatraman Janarthanan.
Founder & CEO,
Oviya MedSafe Pvt. Ltd.
2nd Floor, KTVR Gardens
220a-3, Marudha Konar Road,
Coimbatore – 641 025.
Tamil Nadu, India.